Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: A systematic review and meta-analysis: Effectiveness of ERT in different disease stages

Journal of Inherited Metabolic Disease

Volumn 37, Issue 3, 2014, Pages 341-352

  Rombach, Saskia M ^a   Smid, Bouwien E ^a   Linthorst, Gabor E ^a   Dijkgraaf, Marcel G W ^a   Hollak, Carla E M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA;

CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; DEATH; DISEASE COURSE; END STAGE RENAL DISEASE; ENZYME REPLACEMENT; FABRY DISEASE; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; INCIDENCE; KIDNEY FUNCTION; LONG TERM CARE; META ANALYSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROGNOSIS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; WHITE MATTER LESION; COMPLICATION; FEMALE; GLOMERULUS FILTRATION RATE; HYPERTROPHY, LEFT VENTRICULAR; LEUKOENCEPHALOPATHIES; MALE; PATHOPHYSIOLOGY; STROKE;

ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LEUKOENCEPHALOPATHIES; MALE; STROKE;

EID: 84904156358     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-014-9677-8     Document Type: Review

References (102)

1. Alegra T, Vairo F, de Souza MV, Krug BC, Schwartz IV (2012) Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis. Genet Mol Biol 35:947-954
2. Alfadhel M, Sirrs S (2011) Enzyme replacement therapy for Fabry disease: some answers but more questions. Ther Clin Risk Manag 7:69-82
3. Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M (2003) Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 26: 617-627 (Pubitemid 38008966)
4. Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77-86 (Pubitemid 351640010)
5. Beck M, Ricci R, Widmer U et al (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34:838-844 (Pubitemid 39657931)
6. Beer M, Weidemann F, Breunig F et al (2006) Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 97:1515-1518
7. Bierer G, Balfe D, Wilcox WR, Mosenifar Z (2006) Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 29: 572-579 (Pubitemid 44193273)
8. Borgwardt L, Feldt-Rasmussen U, Rasmussen A, Ballegaard M, Meldgaard LA (2013) Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin Genet 83:432-438
9. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 276:1163-1167
10. Branton MH, Schiffmann R, Sabnis SG et al (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81:122-138 (Pubitemid 34218568)
11. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69:1216-1221
12. Buechner S, Moretti M, Burlina AP et al (2008) Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 79:1249-1254
13. Collin C, Briet M, Tran TC et al (2012) Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease. Eur J Prev Cardiol 19:43-54
14. Crutchfield KE, Patronas NJ, Dambrosia JM et al (1998) Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50:1746-1749 (Pubitemid 28283245)
15. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M (2006) Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43:347-352
16. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188 (Pubitemid 17189972)
17. Desnick RJ, Ioannou YA, Eng CM (2001) alpha-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, vol 3, 8th edn., pp 3733-3774
18. El Dib RP, Nascimento P, Pastores GM (2013) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2, CD006663
19. El Dib RP, Pastores GM (2010) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev CD006663
20. Elliott PM, Kindler H, Shah JS et al (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92:357-360
21. Eng CM, Fletcher J, Wilcox WR et al (2007) Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30:184-192 (Pubitemid 46487999)
22. Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345:9-16 (Pubitemid 32634266)
23. Engelen MA, Brand E, Baumeister TB et al (2012) Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data. BMJ Open 2
24. Eto Y, Ohashi T, Utsunomiya Yet al (2005) Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. J Inherit Metab Dis 28:575-583 (Pubitemid 40753686)
25. Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M (2009) Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol 29:353-361
26. Feriozzi S, Torras J, Cybulla M, Nicholls K, Sunder-Plassmann G, West M (2012) The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol 7:60-69
27. Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547-1557 (Pubitemid 46717522)
28. Grewal RP, Barton NW (1992) Fabry's disease presenting with stroke. Clin Neurol Neurosurg 94:177-179
29. Guffon N (2003) Clinical presentation in female patients with Fabry disease. J Med Genet 40:e38
30. Gupta S, Ries M, Kotsopoulos S, Schiffmann R (2005) The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 84:261-268 (Pubitemid 41368479)
31. Hayden JA, Cote P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144:427-437 (Pubitemid 46768164)
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560 (Pubitemid 37088507)
33. Hollak CE, Aerts JM, Ayme S, Manuel J (2011) Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Dis 6:16
34. Hughes DA, Barba Romero MA, Hollak CE, Giugliani R, Deegan PB (2011) Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS-the Fabry Outcome Survey. Mol Genet Metab 103(3):207-14. doi: 10.1016/j.ymgme.2011.03.022
35. Hughes DA, Elliott PM, Shah J et al (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94:153-158 (Pubitemid 351211719)
36. Imbriaco M, Pisani A, Spinelli L et al (2009) Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart 95:1103-1107
37. Jardim L, Vedolin L, Schwartz IVet al (2004) CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis 27:229-240 (Pubitemid 38756339)
38. Jardim LB, Aesse F, Vedolin LM et al (2006) White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up. Arq Neuropsiquiatr 64:711-717 (Pubitemid 44610624)
39. Kalliokoski RJ, Kantola I, Kalliokoski KK et al (2006) The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis 29:112-118
40. Kampmann C, Linhart A, Baehner F et al (2008a) Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 130:367-373
41. Kampmann C, Linhart A, Devereux RB et al (2009) Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis. Clin Ther 31:1966-1976
42. Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M (2008b) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 97:463-469 (Pubitemid 351432314)
43. Kint JA (1970) Fabry's disease: alpha-galactosidase deficiency. Science 167:1268-1269
44. Kobayashi M, Ohashi T, Sakuma M, Ida H, Eto Y (2008) Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease. J Inherit Metab Dis doi:10.1007/s10545-007-0740-6
45. Koskenvuo JW, Hartiala JJ, Nuutila P et al (2008) Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab Dis 31:432-441
46. Kovacevic-Preradovic T, Zuber M, Attenhofer Jost CH et al (2008) Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy. Eur J Echocardiogr 9:729-735
47. Levey AS, Coresh J, Balk E et al (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137-147
48. Lidove O, West ML, Pintos-Morell G et al (2010) Effects of enzyme replacement therapy in Fabry disease-a comprehensive review of the medical literature. Genet Med 12:668-679
49. Lubanda JC, Anijalg E, Bzduch V, Thurberg BL, Benichou B, Tylki-Szymanska A (2009) Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med 11:256-264
50. MacDermot KD, Holmes A, Miners AH (2001a) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769-775 (Pubitemid 33032933)
51. MacDermot KD, Holmes A, Miners AH (2001b) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750-760 (Pubitemid 33032930)
52. Mehta A, Beck M, Elliott P et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 374:1986-1996
53. Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34:236-242 (Pubitemid 38406640)
54. Messalli G, Imbriaco M, Avitabile G et al (2012) Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy. Radiol Med 117: 19-28
55. Mitsias P, Levine SR (1996) Cerebrovascular complications of Fabry's disease. Ann Neurol 40:8-17 (Pubitemid 26250137)
56. Moore DF, Altarescu G, Herscovitch P, Schiffmann R (2002) Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2:4
57. Motwani M, Banypersad S, Woolfson P, Waldek S (2012) Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol Genet Metab 107:197-202
58. Nakao S, Takenaka T, Maeda M et al (1995) An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333:288-293
59. Niemann M, Breunig F, Beer M et al (2010) The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy. Heart 96:1915-1919
60. Ortiz A, Cianciaruso B, Cizmarik M et al (2010) End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant 25:769-775
61. Patel MR, Cecchi F, Cizmarik M et al (2011) Cardiovascular events in patients with fabry disease natural history data from the fabry registry. J Am Coll Cardiol 57:1093-1099
62. Pisani A, Spinelli L, Sabbatini M et al (2005) Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis 46: 120-127 (Pubitemid 40848440)
63. Pisani A, Spinelli L, Visciano B et al (2013) Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease. JIMD Rep 9:41-48
64. Ramaswami U, Parini R, Kampmann C, Beck M (2011) Safety of agalsidase alfa in patients with Fabry disease under 7 years. Acta Paediatr 100:605-611
65. Ramaswami U, Parini R, Pintos-Morell G, Kalkum G, Kampmann C, Beck M (2012) Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey. Clin Genet 81:485-490
66. Ramaswami U, Wendt S, Pintos-Morell G et al (2007) Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 96:122-127
67. Reisin RC, Romero C, Marchesoni C et al (2011) Brain MRI findings in patients with Fabry disease. J Neurol Sci 305:41-44
68. Ries M, Clarke JT, Whybra C et al (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118: 924-932 (Pubitemid 46091613)
69. Rombach SM, Aerts JM, Poorthuis BJ et al (2012) Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso) Gb3 reduction and treatment outcome. PLoS One 7:e47805
70. Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE (2013) Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 8:47
71. Schiffmann R (2009) Fabry disease. Pharmacol Ther 122:65-77
72. Schiffmann R, Askari H, Timmons M et al (2007) Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 18:1576-1583
73. Schiffmann R, Kopp JB, Austin HA III et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743-2749 (Pubitemid 32525371)
74. Schiffmann R, Martin RA, Reimschisel T et al (2010) Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr 156(832-7):837
75. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345-354 (Pubitemid 43159987)
76. Schiffmann R, Warnock DG, Banikazemi M et al (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24:2102-2111
77. Schwarting A, Dehout F, Feriozzi S, Beck M, Mehta A, Sunder-Plassmann G (2006) Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 66:77-84 (Pubitemid 44219432)
78. Shah JS, Hughes DA, Sachdev B et al (2005a) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 96:842-846 (Pubitemid 41319722)
79. Shah JS, Lee P, Hughes D et al (2005b) The natural history of left ventricular systolic function in Anderson-Fabry disease. Heart 91: 533-534 (Pubitemid 40432794)
80. Sims K, Politei J, Banikazemi M, Lee P (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40:788-794
81. Smid BE, Rombach SM, Aerts JM et al (2011) Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis 6:69
82. Spinelli L, Pisani A, Sabbatini M et al (2004) Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 66:158-165 (Pubitemid 39117524)
83. Tahir H, Jackson LL, Warnock DG (2007) Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 18:2609-2617 (Pubitemid 47378878)
84. Takenaka T, Teraguchi H, Yoshida A et al (2008) Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 51:50-59 (Pubitemid 351699928)
85. Tondel C, Bostad L, Larsen KK et al (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24:137-148
86. Tsuboi K, Yamamoto H (2012) Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). Genet Med 14:779-786
87. Vedder AC, Linthorst GE, Houge G et al (2007a) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2:e598
88. Vedder AC, Linthorst GE, van Breemen MJ et al (2007b) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30:68-78 (Pubitemid 46140228)
89. Wanner C, Oliveira JP, Ortiz A et al (2010) Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry registry. Clin J Am Soc Nephrol 5(12):2220-8. doi: 10.2215/CJN.04340510
90. Warnock DG, Ortiz A, Mauer M et al (2011) Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 27(3):1042-9. doi: 10.1093/ndt/gfr420
91. Warnock DG, Ortiz A, Mauer M et al (2012) Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 27:1042-1049
92. Weidemann F, Breunig F, Beer M et al (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108: 1299-1301 (Pubitemid 37174405)
93. Weidemann F, Niemann M, Breunig F et al (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119:524-529
94. Weidemann F, Niemann M, Stork S et al (2013) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274(4):331-41. doi: 10.1111/joim.12077
95. West M, Nicholls K, Mehta A et al (2009) Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 20:1132-1139
96. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M (2007) Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int 72:632-637 (Pubitemid 47312796)
97. Whybra C, Miebach E, Mengel E et al (2009) A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 11:441-449
98. Wilcox WR, Banikazemi M, Guffon N et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65-74
99. Wilcox WR, Oliveira JP, Hopkin RJ et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112-128
100. Wraith JE, Tylki-Szymanska A et al (2008) Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, openlabel study in pediatric patients with Fabry disease. J Pediatr 152(563-70):570
101. Wuest W, Machann W, Breunig F et al (2011) Right ventricular involvement in patients with Fabry's disease and the effect of enzyme replacement therapy. Rofo 183:1037-1042
102. Wyatt K, Henley W, Anderson L et al (2012) The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess 16:1-543